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Aim: To assess systolic and diastolic function in adult childhood-cancer survivors (CCS)
after treatment entailing potential cardiovascular toxicity.
Methods: The study cohort consisted of 277 adult CCS (median age 28 [range 18–48] years),
who had been treated with anthracyclines, platinum, and/or radiotherapy between 1976
and 1999, along with 130 healthy sibling controls. The assessments included echocardiog-
raphy, baroreflex sensitivity measurement, and plasma N-terminal pro-brain natriuretic
peptide (NT-proBNP). Echocardiography measurements were shortening fraction (SF)
(abnormal < 29%) for systolic function and tissue velocity imaging of early diastole
(TVI Et) (abnormal < 8.00) cm/sec for diastolic function; systolic function was also assessed
by the wall motion score index (WMSI).
Results: At 18 (5–31) years post-treatment, the prevalence of both impaired SF and abnor-
mal WMSI was increased in CCS compared to controls (p = 0.003 and p < 0.001, respectively).
CCS also had an increased prevalence of diastolic dysfunction compared to the controls
(12% versus 1%, p < 0.001). Abnormal SF and/or abnormal diastolic function were found
in 43% of CCS. NT-proBNP was higher in CCS and was associated to increased WMSI.
Baroreflex sensitivity was lower in CCS and was associated with diastolic dysfunction.
Systolic as well as diastolic dysfunction was associated with cumulative dose of
anthracyclines and mediastinal irradiation.
Conclusion: After treatment with potential cardiovascular toxic therapies, the risk of sys-
tolic and diastolic dysfunction in CCS is considerable. Since these abnormalities, in partic-
ular diastolic dysfunction, are age related, the observed effects might be considered a sign
of precocious cardiac ageing.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.Medical Centre Groningen, University of Groningen, Beatrix Children’s Hospital, Division of
0 001, 9700 RB, Groningen, The Netherlands. Tel.: +31 50 3616161; fax: +31 50 3611671.
. Postma).
the Elsevier OA license.
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effects in childhood-cancer survivors (CCS).1 Childhood-
cancer survivors are 15 times as likely to develop clinical heart
failure compared to controls, and the standard mortality rate
for cardiac mortality is significantly increased.1–3 The inci-
dence of overt heart failure in anthracycline-treated survivors
has been found up to 5%.4 However, subclinical abnormalities
in cardiac function are more frequent.5,6
Cardiac and cardiovascular toxicity can be caused by sev-
eral cytostatic drugs, for example vincristine, amsacrine,
mitoxantrone, high-dose cyclophosphamide and ifosfamide,6
but in particular by anthracycline derivates, and also by (con-
comitant) radiation therapy. In addition, late cardiovascular
events have also been described in long-term survivors of tes-
ticular cancer, most of them treated with platinum-based
chemotherapy.7,8 Since it is generally assumed that early
treatment for cardiac disease might benefit survivors’ morbid-
ity and quality of life, early detection of cardiac damage re-
mains a major challenge. Echocardiography is considered
the gold standard for detection of cardiac damage, although
the predictive value of echocardiographic abnormalities with-
out clinical symptoms remains unclear.9 Other monitoring
strategies for early detection of cardiac damage include bio-
chemical markers (NT-proBNP, troponin) and autonomic func-
tion.10,11 The role of comorbidity also has to be considered as
CCS are at risk for metabolic abnormalities.12
Cardiomyopathy in CCS is generally expressed as systolic
dysfunction.5,6,12,13 The increased risk of systolic dysfunction
in association with previous anthracycline treatment is well
known, especially after a higher cumulative dose.13,14 It has
been suggested that cytostatic treatment (i.e. anthracyclines
or cisplatin) may also result in diastolic dysfunction, although
diastolic cardiac dysfunction in CCS has been described only
in a limited number of studies.15–17 However, as is known
from the general population, systolic as well as diastolic dys-
function can be a predictor for clinical heart failure.18
Radiation-induced cardiac damage has been recognised
especially in long-term survivors of Hodgkin’s disease and may
manifest itself in the myocardium, the pericardium, or the coro-
nary vessels, or as valvular heart disease.19,20 Radiotherapy (RT)
of the chest has been associated with both systolic and diastolic
dysfunction, or with diastolic dysfunction without systolic
dysfunction.19,21 The increasedrisk of heart failure from medias-
tinal radiotherapy is further augmented by anthracyclines.20
We assessed cross-sectionally the prevalence of systolic
and diastolic dysfunction and its association with previous
treatment in a large cohort of adult CCS five or more years
after completion of treatment characterised by potential car-
diovascular toxicity, and we compared the results with those
of sibling controls.
2. Patients and methods
2.1. Study design and participant’s eligibility and
recruitment
Participants were invited to participate in this single centre
study with the scope on cardiovascular disease and cardio-1999; (b) treatment characterised by potential cardiovascular
toxicity (anthracyclines, platinum, and/or RT) on mediasti-
num (including mantle field), spine or total body; (c) age at
diagnosis 6 20 years; (d) current ageP 18 years; (e) surviving
at least 5 years after diagnosis; and (f) no cardiovascular dis-
ease pre-existent to the cancer diagnosis and/or down syn-
drome. These criteria were fulfilled by 467 patients, 46 of
whom had died 5 years or more after diagnosis (secondary
tumour/late relapse 35, cardiac death one, other causes 10).
Exclusion criteria were current treatment for late relapse or
secondary tumour (n = 15), or mental incapacity (n = 5).
Consequently 401 CCS were eligible. Seventeen CCS were
lost-to-follow-up. The remaining 384 CCS were invited to par-
ticipate in the study. Two hundred seventy-seven of the
invited 384 CCS (72%; 69% of eligible CCS) agreed to partici-
pate in the study and 107 (28%) refused. No differences in
age at diagnosis, sex, duration of cancer treatment, and type
of cancer treatment were found between the 277 participating
and 124 eligible non-participating subjects. In participants the
median time since diagnosis at the initiation of the study was
17.7 years versus 15.2 years in non-participants (p = 0.008).
Twenty-seven of the 277 participating CCS (10%) in this study
had survived treatment for a relapse. Fourteen CCS were on
growth hormone replacement therapy. Eight CCS were receiv-
ing cardioactive medication (ACE-inhibitor, b-blocker or diure-
tic) for systolic heart failure that had been diagnosed
previously (n = 7) or for renal tubular dysfunction (n = 1). At
the time of the current assessment, all participating CCS were
P5 years off-treatment. The number of participants was
based on a power calculation. With an anticipated number
of 270 participating CCS and 125 control subjects the power
to detect a difference in prevalence of cardiac damage of
15% was 81% with a double sided significance level of
p = 0.05. Control subjects were recruited among those healthy
siblings nearest to them in age (n = 130).
The study protocol was approved by the Ethics Committee
of the University Medical Centre Groningen. Written in-
formed consent was obtained from all participants. All
assessments were performed between August 2004 and April
2007.
2.2. Clinical and cardiac assessments
Childhood-cancer survivors and controls underwent assess-
ment of their medical history, a physical examination, blood
sampling, echocardiography, and baroreflex sensitivity (BRS).
Within the scope of the study, the participants also under-
went vascular assessments, and endothelial and inflamma-
tory marker proteins. The results of the vascular
assessments will be published separately.
Medical history was assessed by means of a standardised
interview. Details of previous cancer treatment and medica-
tion were retrieved from medical records. Blood pressure
was measured twice on both arms in supine position in a
quiet room after a minimal rest period of ten minutes. The
mean of the lowest blood pressure measurements on both
arms was taken for analysis. The criteria for hypertension
were systolic blood pressure P140 mmHg, diastolic blood
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drugs. The eight CCS who received cardioactive medication
(ACE-inhibitor, b-blocker, or diuretic) for systolic heart failure
(n = 7) or renal tubular dysfunction (n = 1) were excluded from
the assessment of the prevalence of hypertension. Body mass
index (BMI; weight (kg)/height2 (m2)) was considered to reflect
body composition. Underweight was defined as BMI < 18.5
kg/m2, overweight as BMIP 25 kg/m2.
After an overnight fast, blood was drawn in the morning,
and analysed for serum electrolytes, liver enzymes, creati-
nine and lipid levels: total cholesterol (normal < 5.2 mmol/
L), LDL cholesterol (normal < 4.7 mmol/L), HDL cholesterol
(normal males 0.90–1.50 mmol/L, females 1.10–1.70 mmol/L)
and triglycerides (normal males < 2.28 mmol/L, females <
2.05 mmol/L), troponin, and N-terminal pro-brain natriuretic
peptide (NT-proBNP). Plasma troponin measurement was by
troponin I (normal < 0.04 lg/L) until March 2006 and by
troponin T (normal < 0.01 lg/L) afterwards, according to
laboratory routine. NT-proBNP was measured in heparin
plasma stored at -80C using an immuno-assay (Elecsys
2010; Roche Diagnostics, Lewes, United Kingdom; normal
value 6125 ng/L).
Echocardiography was performed by a single skilled tech-
nician (masked to the treatment versus the control group)
on a General Electric VIVID 7 system with a 2.5 mHz probe,
and consisted of two-dimensional echocardiography, colour
flow mapping, and 2D-guided M-mode, blood pool, and tissue
velocity imaging.22 Dimensions (intra-ventricular septal
thickness end-diastolic [IVSed], left ventricular [LV] posterior
wall thickness end-diastolic [LVPW(ed)], LV end-diastolic
dimension measured in 2D [LVEDD], LV end-systolic dimen-
sion [LVESD], and length and traverse of left atrium (LA)) were
measured as previously described in detail,15 and were cor-
rected for body surface area. LV systolic function was deter-
mined by shortening fraction (SF; LVEDD-LVESD/
LVEDD · 100%). A SF < 29% was considered abnormal.23 In
addition, we also determined the wall motion score index
(WMSI) as a measurement of systolic function. Unlike SF
which takes only movement of the septum and the posterior
wall of the LV into account, the WMSI takes all LV wall seg-
ments into account.24 WMSI is an accurate index of systolic
function, which correlates to ejection fraction (EF) without
the variability that is common in EF.25,26 For measurement
of WMSI, the LV wall was divided into 16 segments. Each seg-
ment was visually scored between 1 and 4 (1 = normokinesia;
2 = hypokinesia; 3 = akinesia; 4 = dyskinesia), and the WMSI
was the mean score for all the segments analysed; by defini-
tion a normal WMSI is 1.00 and a WMSI >1.00 is abnormal.
Diastolic function measurements included mitral valve inflow
velocities in early (E) and late (A) diastole (E/A ratio), and dia-
stolic tissue velocity at the mitral valve annulus (Tissue Veloc-
ity Imaging of early diastole (TVI Et)). The TVI Et was
measured at four segments, that is, septal, lateral, anterior,
and posterior, and the mean value of these segments was cal-
culated. A TVI Et mean < 8.0 cm/sec was considered diastolic
dysfunction.27 An additional parameter for diastolic function
was E/TVI Et (E/E’)-ratio.27 Cardiac autonomic function was
assessed using BRS calculated from Finapres blood pressure
and heart rate recordings, as previously described in detail.28
BRS (ms/mmHg) was determined by the transfer functiontechnique using the CARSPAN software programme, and val-
ues were given as natural logarithms.29 BRS was analysed as a
continuous variable without a cut-off value.2.3. Treatment variables
To evaluate the late cardiovascular toxic effects of the treat-
ment administered, the following chemotherapy categories
were analysed: (1) anthracycline-based combination (doxoru-
bicin, daunorubicin) chemotherapy; and (2) platinum-based
combination (cisplatin, carboplatin) chemotherapy. None of
the survivors had received epirubicin, idarubicin or liposomal
anthracyline derivates. In addition to anthracyclines, two
patients also had mitoxantrone and one patient also had
mitoxantrone and amsacrine. To evaluate the effect of RT,
the following radiation fields were considered: (1) any type
of RT, except RT on the extremities, and (2) chest RT (RT of
mediastinum, mantle field, spine or total body RT (TBI)). At
the time most of the patients in our study group had received
RT the data were not stored, precluding accurate retrospective
estimation of the radiation dose to the heart. Cardiac radia-
tion dose was considered to be low in the CCS who had re-
ceived spinal RT (645 Gy spinal RT, estimated RT dose on
the heart < 25 Gy) or TBI (612 Gy TBI in one or two fractions,
estimated RT dose on the heart equivalent to <20 Gy).30,312.4. Data analyses and statistics
Since anthracycline cardiotoxicity is related to cumulative
dose, the results were analysed for cumulative doses below
and above the median of the current study population (i.e.
183 mg/m2). Platinum was included in the analysis as a yes/
no-variable. As the median mediastinal irradiation dose was
25 Gy, the results of the cardiac assessments were analysed
for <25 Gy and for P25 Gy. Statistical analyses were per-
formed using SPSS Inc., version 14. Two-sided p-values < 0.05
were considered significant.
Differences between survivors and controls were tested
with Chi-square tests (categorical variables, Fisher exact test
in case >20% of the cells had an expected count less than 5),
Mann–Whitney U tests (non-Gaussian distributed variables),
and T-tests (Gaussian distributed variables).
Multivariate logistic and linear regression analyses were
used to assess the association between the primary outcome
measurements (systolic dysfunction, defined as SF < 29% or
as WMSI > 1.00, and diastolic dysfunction, defined as TVI Et
mean < 8.00 cm/sec) and the secondary outcomes (abnormal
NT-proBNP [>125 ng/L] and BRS [as a continuous variable])
as dependent variables, and the treatment variables as inde-
pendent variables. First, each of the treatment variables was
tested in a separate model with adjustment for possible con-
founders, that is, age at diagnosis, sex, current age, follow-up
period post-treatment, hypertension, BMI, and use of poten-
tially interfering medication (ACE-inhibitor, diuretic, b-block-
er or GH-replacement therapy). Second, the treatment
variables with a significant association (based on a more lib-
eral p-value < .10) in these separate models were entered
simultaneously in the same model in order to correct the ef-
fect of the specific treatment for the other treatments.
Table 1 – Cancer-related characteristics of the participating
277 survivors.
Survivors (n = 277)
Age at diagnosis – years a 8.8 (0.0–20 1)
Follow-up post-treatment – years a 18.2 (5.4–30.8)
Cancer diagnosis, No. (%)
Leukaemia 113 (41)
Acute lymphoblastic leukaemia 103
Acute non-lymphoblastic leukaemia
9
Acute undifferentiated leukaemia 1
Malignant lymphoma 56 (20)
Sarcoma 48 (17)
Brain tumour 32 (12)
Blastomab 23 (8)
Germ cell tumour 5 (2)
Chemotherapy, No. (%)
Combination chemotherapy
including anthracyclines
199 (72)
Doxorubicin 100 (36)
Daunorubicin 53 (19)
Both doxorubicin and daunorubicin 46 (17)
Anthracycline dosePmedian
(183 mg/m2)
100 (36)
Combination chemotherapy
including platinum
22 (8)
Radiation therapy, No. (%)
Radiation therapy 174 (63)
Whole chest RT 69 (25)
Mediastinal RT 33 (12)
TBI 17 (6)
Spinal RT 19 (7)
Dose of mediastinal RT P25 Gy 17 (6)
Combination of treatment modalities, No. (%)
Anthracylines and platinum 11 (4)
Chest RT and anthracyclines 45 (16)
Chest RT and platinum 6 (2)
Chest RT and anthracyclines
and platinum
2 (1)
a Median (range).
b Nephroblastoma, neuroblastoma; RT, radiotherapy; TBI, total body
irradiation.
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3.1. Study population
Two hundred seventy-seven CCS and 130 sibling controls
underwent a cardiac assessment at the median of 18 years
post-treatment (range 5–31).
The treatment characteristics of the participants are sum-
marised in Table 1. Basic characteristics and cardiovascular
risk factors are summarised in Table 2. Distribution of age
and sex was comparable between the CCS and the controls.
Serum creatinine levels in CCS and controls were comparable
(median 71 (42–146) lmol/L versus 73 (52–109 lmol/L, p = 0.21).
Cumulative doses of anthracyclines ranged from 50 to
600 mg/m2 (median 183 mg/m2). Thirty-two out of 275 CCS
(12%, 2/277 unknown) and none of the controls had cardioac-
tive medication, statins, or growth hormone replacement
therapy. Seventeen had cardioactive medication, two had
statins and 14 had growth hormone replacement therapy;
one of these CCS had cardioactive medication as well as a sta-
tin. Although BMI in CCS was comparable to BMI in controls
(p = 0.07), CCS had more underweight compared to the con-
trols (p = 0.008); the prevalence of overweight (p = 0.46) and
hypercholesterolemia (p = 0.25) was not significantly different
between the CCS and the controls. More controls than survi-
vors reported ever smoking (p = 0.04). Ninety-six percent of
the CCS and 99% of the controls were classified as New York
Heart Association Class 1; the remaining subjects were classi-
fied as Class 2 (p = 0.11).32
3.2. Cardiac parameters in CCS and controls (Table 3)
3.2.1. Systolic function
Systolic function was studied using different parameters: SF
as well as WMSI. Systolic dysfunction, defined as SF < 29%,
was evaluable in 274 CCS and 130 controls. SF was impaired
in 100/274 (37%) of the CCS versus 28/130 (22%) of the controls
(p = 0.003). Median SF was lower in the CCS compared to the
controls (31.7% versus 32.7%, p = 0.007). WMSI was evaluable
in 267 CCS and in 128 controls. Abnormal WMSI, defined as
WMSI > 1.00, was found in 39/267 (15%) of the CCS versus
2/128 (2%) of the controls (p < 0.001). In both CCS and controls
the prevalence of abnormal WMSI was lower than the preva-
lence of impaired SF (CCS: 15% versus 37%; p < 0.001, controls:
2% versus 22%; p = 0.04). Results for SF as well as for WMSI
were available in 267 CCS. In 80 of them either SF or WMSI
were abnormal, in 28 CCS both SF as WMSI were abnormal
and in 159 CCS both SF and WMSI were normal. CCS with
both abnormal SF and WMSI (n = 28) had more often received
a cumulative dose of anthracyclines above the median dose of
183 mg/m2 (odds ratio (OR) 2.64; 95% confidence interval (CI)
1.12–6.25, p = 0.03). The combined presence of abnormal SF
and WMSI was not associated with prior treatment with any
RT or mediastinal RT.
3.2.2. Diastolic function
Diastolic function, expressed as TVI Et, was evaluable in 273
CCS and in 129 controls. Diastolic dysfunction, defined as
TVI Et < 8.0 cm/sec, was found in 32/273 (12%) of the CCS
versus 1/129 (1%) of the controls (p < 0.001). TVI Et mean waslower in the CCS compared to the controls (p < 0.001), E/A ratio
was lower in the CCS compared to the controls (p = 0.02) and E/
E 0 was higher in CCS compared to controls (p < 0.001).
3.2.3. Systolic and diastolic function
Systolic dysfunction was studied using the parameters SF as
well as WMSI
1. Systolic function defined as SF < 29%. Both SF and TVI Et
were available in 272 CCS and in 129 controls. Systolic
dysfunction with normal diastolic function (SF < 29%
and TVI EtP 8.00 cm/sec) was found in 86/272 CCS and
in 27/129 controls. Diastolic dysfunction with normal
systolic function (SFP 29% and TVI Et < 8.0 cm/sec) was
found in 17/272 CCS and 1/129 controls. Systolic as well
as diastolic dysfunction (SF < 29% and TVI Et < 8.0 cm/
sec) was found in 14/272 CCS and in 0/129 controls.
Table 2 – General characteristics and cardiovascular risk factors in 277 childhood cancer survivors and 130 controls.
Survivors Controls p-Value
Characteristics
Sex, No. (%) 0.40
Male 155 (56) 67 (52)
Female 122 (44) 63 (48)
Age at cardiac evaluation – yearsa 27.5 (18.1–48.2) 25.9 (18.0–51.1) 0.33
NYHA heart failure classification, Nb (%) 0.11c
Class 1 263/274 (96) 129/130 (99)
Class 2 11/274 (4) 1/130 (1)
Use of cardioactive medication, Nb (%)d 17/275 (6) 0/130 (0) 0.004
Use of statins, Nb (%) 2/275 (1) 0/130 (0) 1.00c
Growth hormone replacement therapy, Nb (%) 14/275 (5) 0/130 (0) 0.006c
Ever smoking, Nb (%) 102/275 (37) 62/130 (48) 0.04
Cardiovascular risk factors
Hypertensione, Nb (%) 38/263 (14) 10/130 (8) 0.05
BMI (kg/m2)a 22.8 (16.4–46.3) 23.7 (17.6–35.0) 0.07
Underweight (BMI < 18.5 kg/m2; Nb (%)) 19/274 (7) 1/130 (1) 0.008
Overweight (BMIP 25 kg/m2; Nb (%)) 91/274 (33) 48/130 (37) 0.46
Hypercholesterolemiaf, Nb (%) 80/245 (33) 33/123 (27) 0.25
Serum creatinine level lmol/La 71 (42–146) 73 (52–109) 0.21
a Median (range); No., number; NYHA, New York Heart Association; NYHA Class 1, indicated no symptoms and no limitation in ordinary
physical activity; NYHA Class 2, indicated mild symptoms and slight limitation during ordinary activity and comfortable at rest31; BMI, body
mass index.
b Number/number evaluable subjects.
c p-Values based on Fisher’s exact test.
d Cardioactive medication: ACE-inhibitor, b-blocker or diuretic.
e Hypertension: systolic blood pressure P140 mmHg and/or diastolic blood pressure P90 mmHg and/or use of antihypertensive medication
(excluding eight survivors with cardiac treatment because of previously diagnosed systolic heart failure (n = 7) or renal tubular dysfunction (n = 1)
and without hypertension).
f Hypercholesterolemia: fasting LDL cholesterol P3.4 mmol/L and/or use of cholesterol lowering medication (statins).
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(43%) CCS had systolic dysfunction and/or diastolic
dysfunction.
2. Systolic function defined as WMSI > 1. Both WMSI and TVI
Et were available in 267 CCS and 127 controls. Systolic dys-
function with normal diastolic function (WMSI > 1 and TVI
EtP 8.00 cm/sec) was found in 31/267 CCS and in 2/127
controls. Diastolic dysfunction with normal systolic func-
tion (WMSI = 1 and TVI Et < 8.0 cm/sec) was found in 20/
267 and in 1/127 controls. Systolic as well as diastolic dys-
function (WMSI > 1 and TVI Et < 8.0 cm/sec) was found in
8/267 CCS and in 0/127 controls. When systolic function
was expressed as WMSI, 59/267 (22%) CCS had systolic dys-
function and/or diastolic dysfunction.3.2.4. Hypertension
The prevalence of hypertension was not significantly differ-
ent between the CCS and the controls (p = 0.05) (Table 2).
Hypertension was found in 13/92 (14.1%) of evaluable survi-
vors with SF < 29%), in 5/33 (15.2%) of evaluable survivors with
WMSI > 1, and in 17/29 (58.6%) of evaluable survivors with dia-
stolic dysfunction.
3.2.5. Biochemical markers
NT-proBNP assessment was available in 262 CCS and in 127
controls. NT-proBNP was significantly higher and more often
elevated in the CCS compared to the controls (Table 3).
NT-proBNP was abnormal in 16/97 evaluable CCS (16%) withsystolic dysfunction defined as SF < 29%, in 12/38 evaluable
CCS (32%) with systolic dysfunction defined as WMSI > 1.00
and in 4/30 (13%) CCS with diastolic dysfunction, defined as
TVI Et < 8.00 cm/sec. Elevated NT-proBNP was associated with
systolic dysfunction defined as WMSI > 1.00 (p 6 .001). NT-
proBNP was not associated with systolic dysfunction defined
as SF < 29% and diastolic dysfunction. Troponin was abnormal
in 3/268 (1%) CCS, all of them with normal renal function, ver-
sus none of the controls (p = 0.55). None of the CCS with sys-
tolic and/or diastolic dysfunction had an abnormal troponin.
3.2.6. Autonomic function
The mean BRS was significantly lower in the CCS compared to
the controls (p = 0.01), indicating autonomic dysfunction in
the CCS. A lower BRS was associated with diastolic dysfunc-
tion (p = 0.001), not with systolic dysfunction (defined as
SF < 29%: p = 0.87, defined as WMSI > 1.00: p = 0.29).
3.3. Treatment-related factors and cardiac dysfunction
The results of logistic regression analyses with systolic and
diastolic dysfunction as dependent variables are summarised
in Table 4.
3.3.1. Systolic dysfunction (SF < 29%)
None of the potential confounders was associated with sys-
tolic dysfunction, defined as SF < 29%. In the logistic regres-
sion models with the different treatment modalities entered
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ers, SF < 29% was associated with anthracyclines (OR 2.15;
95% CI 1.08–4.26), with cumulative dose of anthracy-
clinesPmedian (i.e. 183 mg/m2, OR 2.01; 95% CI 1.17–3.47),
and with chest RT (OR 2.04; CI 1.12–3.70), especially mediasti-
nal RT (OR 2.75; 95% CI 1.25–6.05). In the model with the treat-
ment modalities entered simultaneously, these associations
remain significant (anthracyclinesPmedian: OR 2.18; 95%
CI 1.25–3.80, mediastinal RT: OR 3.00; 95% CI 1.35–6.67).
3.3.2. Systolic dysfunction (WMSI > 1.00)
Of the potential confounders included, only the cardioactive
medication (OR 19.6; 95% CI 3.5–108.9) and the GH replace-
ment therapy (OR 5.2; 95% CI 1.4–20.0) were associated with
systolic dysfunction, defined as WMSI > 1.00. In the adjusted
logistic regression models with the treatment modalities en-
tered separately, a WMSI > 1.00 was only associated with a
cumulative anthracycline dosePmedian (OR 3.32; 95% CI
1.07–5.04) and this remained significant after adjustment for
chest RT by localisation (OR for anthracycline dosePmedian
2.40; 95% CI 1.10–5.25).
3.3.3. Diastolic dysfunction (TVI Et < 8.0 m/sec)
Of the potential confounders included, age (OR 1.3; 95% CI
1.2–1.6), female sex (OR 0.3; 95% CI 0.1–0.97), hypertensionTable 3 – Cardiac parameters in 277 childhood cancer survivors
S
Echocardiography
Systolic function
SF (%), median (range) 31.7
SF < 29%, na(%) 100/
WMSI > 1.00 39/2
Diastolic function
E/A ratio 1.63
E/A ratio < 1.00, na (%) 14/2
TVI Et mean (cm/sec) 10.6
TVI Et < 8 cm/sec, na (%) 32/2
E/E 0 median (range) 8.6
Cardiac dimensions (in mm; BSA corrected)
BSA median (range) 1.85
IVSed, mean ± SD 4.3 ±
LVPWed, mean ± SD 4.3 ±
LVEDD, mean ± SD 25.3
LVESD, mean ± SD 17.3
LA parasternal, mean ± SD 17.5
LA length, mean ± SD 28.2
LA transverse, mean ± SD 21.0
Autonomic function
Natural log mean BRS (ms/mmHg), mean ± SD 2.4 ±
Range 0.6–
Biochemical markers
NT-proBNP (ng/L), median (range) 47 (
NT-proBNP > 125 ng/L, na (%) 32/2
Abnormal troponin, na (%) 3/26
a Number/number evaluable subjects. SF, shortening fraction; SD, standa
IVS, interventricular septum; LVPW, left ventricular posterior wall; LVEDD
systolic diameter; LA, left atrium; BRS, baroreflex sensitivity; NT-proBNP, N(OR 8.4; 95% CI 2.9–24.1), and BMI (OR 1.1; 95% CI 1.0–1.2) were
associated with diastolic dysfunction, defined as TVI
ET < 8 cm/sec. In the adjusted logistic regression models with
the treatment modalities entered separately, diastolic dys-
function was associated with a cumulative anthracycline do-
sePmedian (OR 3.04; 95% CI 1.02–9.03) and with chest RT (OR
4.27; 95% CI 1.42–12.87), especially mediastinal RT (OR 12.33;
95% CI 2.97–51.14) and mediastinal RTP 25 Gy (OR 28.12;
95% CI 4.69–168.74). In the model with the treatment modali-
ties entered simultaneously, these associations remain
significant (anthracyclinesPmedian: OR 4.05; 95% CI
1.16–14.09, mediastinal RT: OR 15.21; 95% CI 3.40–68.01).
Additional adjustment for blood creatinine and glucose
levels did not change the results of the analyses on systolic
and diastolic dysfunction (data not shown). A statistical
analysis was also performed after exclusion of the CCS who
were on cardiac medication. The results were not different
from those of the entire cohort (data not shown).
3.3.4. NT-proBNP and BRS
The results of the regression analyses performed with an
elevated NT-proBNP (logistic regression) and BRS (linear
regression) as dependent variables showed that an elevated
NT-proBNP was associated with cumulative anthracycline do-
sePmedian (OR 4.0; 95% CI 1.5–11.0) and with mediastinal RTand 130 controls.
urvivors Controls P-value
(16.7–57.9) 32.7 (21.4–48.0) 0.007
274 (37%) 28/130 (22%) 0.003
67 (15%) 2/128 (2%) <0.001
± 0.50 1.74 ± 0.41 0.02
73 (5.1%) 2/130 (1.5%) 0.08
± 2.2 12.4 ± 1.6 <0.001
73 (12%) 1/129 (1%) <0.001
(5.1–30.0) 7.7 (4.7–12.5) <0.001
(1.28–2.64) 1.92 (1.55–2.42) 0.001
0.5 4.3 ± 0.6 0.85
0.6 4.2 ± 0.5 0.13
± 2.4 25.1 ± 2.0 0.41
± 2.3 16.8 ± 2.1 0.03
± 1.9 17.5 ± 1.7 0.98
± 2.8 28.0 ± 2.6 0.37
± 2.8 21.0 ± 2.4 0.92
0.6 2.6 ± 0.6 0.01
4.1 0.9–5.3
11–4758) 34 (11–257) <0.001
62 (12%) 4/127 (3%) 0.004
8 (1%) 0/130 (0%) 0.55
rd deviation; WMSI, wall motion score index; BSA, body surface area;
, left ventricular end-diastolic diameter; LVESD, left ventricular end-
-terminal pro-brain natriuretic peptide.
Table 4 – Logistic regression analysisa with systolic (SF, WMSI) and diastolic function (TVI Et) as dependent variables.
Independent variables SF < 29% WMSI > 1.00 TVI Et < 8.0 m/sec
OR 95% CI P OR 95% CI P OR 95% CI P
Each treatment variable entered separately
Anthracyclines (n = 199) 2.15 1.08–4.26 .03 1.59 0.58–4.40 .37 1.46 0.43–4.99 .55
Dose anthracyclinesPmedian (183 mg/m2) (n = 100) 2.01 1.17–3.47 .01 3.32 1.07–5.04 .03 3.04 1.02–9.03 .05
Platinum (n = 22) 0.67 0.25–1.84 .44 0.67 0.16–2.72 .57 2.29 0.33–15.95 .40
Any RT (n = 174) 0.92 0.53–1.61 .78 0.82 0.37–1.81 .62 0.84 0.27–2.61 .76
Chest RT (n = 69) 2.04 1.12–3.70 .02 1.05 0.45–2.45 .92 4.27 1.42–12.87 .01
Dose of mediastinal RTP 25 Gy (n = 17) 2.34 0.83–6.60 .11 2.58 0.71–9.44 .15 28.12 4.69–168.74 <.001
Chest RT by localisation
Mediastinal RT (n = 33) 2.75 1.25–6.05 .01 1.40 0.45–4.29 .56 12.33 2.97–51.14 .001
TBI (n = 17) 1.70 0.59–4.93 .33 0.78 0.17–3.50 .74 1.62 0.10–25.14 .73
Spinal RT (n = 19) 1.23 0.36–4.18 .74 0.79 0.12–5.25 .81 0.74 0.08–6.92 .80
Treatment variables entered simultaneously
Dose anthracyclinesPmedian (183 mg/m2) and chest RT by localisation
Dose anthracyclinesPmedian 2.18 1.25–3.80 .006 2.40 1.10–5.25 .03 4.05 1.16–14.09 .03
Mediastinal RT 3.00 1.35–6.67 .007 1.61 0.51–5.02 .42 15.21 3.40–68.01 <.001
TBI 1.89 0.64–5.60 .25 0.82 0.18–3.78 .80 2.89 0.18–46.77 .45
Spinal RT 1.40 0.40–4.90 .60 0.79 0.11–5.57 .81 1.12 0.11–11.54 .93
Bold: significant. SF, shortening fraction; WMSI, wall motion score index; RT, radiotherapy; TBI, total body irradiation; OR, odds ratio; CI,
confidence interval.
a Corrected for age at diagnosis, sex, current age, follow-up period post-treatment, hypertension, BMI, and use of potentially interfering
medication (ACE-inhibitor, diuretic, b-blocker or GH-replacement therapy).
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both treatment modalities entered simultaneously). No asso-
ciation was found between BRS and the different treatment
groups (data not shown).
4. Discussion
In this cross-sectional long-term follow-up study we found a
significantly higher prevalence of systolic and diastolic dys-
function in a large cohort of adult CCS compared to sibling
controls. At a median follow-up of 18 years post-treatment,
the prevalence of systolic and/or diastolic dysfunction was
as high as 43%, when SF was used to measure systolic func-
tion and 22% when WMSI was used to measure systolic func-
tion. Most survivors with diastolic dysfunction (TVI
Et < 8.00 cm/sec) had normal systolic function (SFP 29%).
These results are of importance, since in the general popula-
tion not only systolic dysfunction, but also diastolic dysfunc-
tion predicts clinical heart failure and sudden cardiac death.18
Diastolic function is not well established in CCS and has
been described in only a few studies.15,16,33 The major draw-
backs of those studies are their limited size, their use of
load-dependent echocardiography parameters such as
E/A-ratio or the lack of healthy controls. Load-dependent dia-
stolic parameters have the disadvantage that differences in
LV filling may interfere with correct interpretation, thus
prompting conflicting results.34 Diastolic dysfunction of the
heart is ideally assessed by an invasive approach.27 However
the invasive approach is burdensome and therefore a non-
invasive approach is preferable for the assessment of a cancer
survivor population and healthy controls. TVI Et, being inde-
pendent of LV filling, is currently considered the most reliable
non-invasive technique for assessing diastolic dysfunction.34
In our data, we found no difference in prevalence of an abnor-mal E/A ratio between the CCS and the controls, whereas TVI
was significantly more often abnormal in CCS (12% versus
1%). In survivors of adult cancer, TVI showed progressive
impairment several years after anthracycline treatment when
compared to baseline before treatment.35
In our study we found that systolic and diastolic dysfunc-
tions were associated with a higher cumulative dose of anth-
racyclines and with mediastinal irradiation (Table 4). This is
in accordance with the results of several other studies which
suggested that diastolic dysfunction, measured by load-
dependent variables, was associated with both anthracyclines
and chest RT,15,19,36 other studies showed conflicting results,
however. Hudson and colleagues found that in CCS a de-
creased SF was associated with a cumulative anthracycline
dose P270 mg/m2 but not with whole heart RT; others, how-
ever, demonstrated earlier that systolic dysfunction, ex-
pressed as ejection fraction, was associated with RT of the
cardiac region.13,21,37 In the current study systolic and/or dia-
stolic dysfunction was not associated with platinum, whereas
in an earlier study on platinum treated survivors of testicular
cancer we found a significant decrease in TVI Et and E/A ratio
1 year after treatment.8 As the number of platinum treated
CCS in the current study was only 22, lack of power could play
a role, as well as a difference in duration of follow-up.
Plasma NT-proBNP, troponine and BRS were evaluated as
additional parameters in the cardiac risk assessment.
NT-proBNP was higher in the CCS compared to the controls,
and a higher cumulative anthracycline dose as well as medi-
astinal RT was associated with an elevated NT-proBNP. There
was no relationship between diastolic dysfunction and
NT-pro-BNP. As for systolic dysfunction, NT-proBNP was re-
lated with WMSI, but not with SF. This could suggest that
WMSI is a more precise measurement of systolic function
than SF. Troponine levels were not different in CCS and
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systolic or diastolic dysfunction. In this study only three long-
term CCS had elevated troponine levels, and none of them
had echocardiographic abnormalities. Compared to the sib-
ling controls, BRS was lower in CCS, suggesting autonomic
cardiac dysfunction. A lower BRS was associated with dia-
stolic dysfunction. None of the treatment factors in this study
was found to be associated with BRS. In a previous study we
did in high-dose anthracycline-treated bone tumour survi-
vors who were found to have systolic and diastolic dysfunc-
tion, we also observed autonomic dysfunction.15 As a low
BRS is known to be a predictor of all-cause mortality and sud-
den death in various patient groups,38 autonomic dysfunction
in CCS may be a sensitive early parameter of cardiac
morbidity.
Although hypertension is known to be of predictive value
in the development of diastolic dysfunction,27 in the current
study more than 40% of CCS with diastolic dysfunction had
no hypertension. This suggests that there are additional
mechanisms that play a role in the oetiology of diastolic dys-
function in CCS which have still to be unravelled. One of those
mechanisms could be precocious cardiovascular ageing, since
in the general population diastolic dysfunction is associated
with advanced age,18,39 with increased vascular and ventricu-
lar stiffness as integral manifestations of ageing.34 The finding
of an increased prevalence of diastolic dysfunction at a med-
ian age of 28 years in our population of young adult CCS is a
good fit with the concept of precocious cardiovascular ageing.
Recently, Maccormick and colleagues elaborated the theoreti-
cal mechanisms of ageing and its potential acceleration by
chemotherapy.40 One of the ageing theories is based on
free-radical damage. Anthracycline metabolism generates
free-radical intermediates that can damage cardiac tissue.40
Radiation has been described in association with atheroscle-
rosis, which is an integral component of ageing.41 The exact
mechanism needs to be elucidated, but RT-induced endothe-
lial injury has been suggested as an initiator in the develop-
ment of atherosclerosis.30,31 Further research is warranted to
explore the hypothesis of accelerated ageing in CCS and its ef-
fect on vital organs such as the heart and the vascular system.
Although treatment for asymptomatic systolic dysfunction
has been well established in patients with cardiac problems
due to causes other than childhood cancer treatment,42 treat-
ment for symptomatic and asymptomatic diastolic dysfunc-
tion in patients with cardiac problems due to causes other
than childhood cancer treatment is still controversial, and
has yet to be evaluated in clinical trials.43 Thus far, the ap-
proach to subclinical diastolic dysfunction has been limited
to identification and treatment of the underlying cause(s) of
diastolic dysfunction (e.g. hypertension, overweight).
Cardiac toxicity further unfolds to become a considerable
problem in CCS. Cardiac mortality is reported to be about
six times higher in CCS compared to controls,1 while data
on cardiac morbidity show variable results.5,6 Thus far, car-
diac dysfunction has mainly been characterised by parame-
ters of systolic function.5,12,37,44 In paediatric oncology and
in studies of CCS, systolic function is commonly expressed
as measured by SF. However, in many studies in cardiology
the WMSI is used rather than SF. This is based on the fact that
the WMSI is actually a more precise measurement of systolicfunction than SF, since it takes all 16 segments of the LV wall
into account as opposed to essentially only two segments in
SF. We therefore decided to use the WMSI in addition to SF.
Abnormal WMSI was found in 15% of CCS versus 2% of con-
trols, whereas an abnormal SF was found in 37% of CCS and
in 22% of the controls. The high prevalence of abnormal SF
in apparently healthy sibling controls suggests the possibility
of false-positive findings and challenges the appropriateness
of SF as a reliable marker of systolic function in adults.
The strengths of our study are its large sample size, the ex-
tended follow-up period, the sibling controls, and the ad-
vanced contemporary echocardiography. Moreover, all the
echocardiograms were performed by a single skilled techni-
cian, thus reducing inter-observer variability. However, there
are some limitations. First of all, the cohort is very heteroge-
neous. Indeed, due to the rarity of paediatric cancer, most sin-
gle-institutional long-term follow-up studies of childhood
cancer survivors involve heterogeneous patient populations.
To overcome this, we used regression analyses to adjust for
possibly confounding variables. Another limitation is the
cross-sectional nature of the study design, which precludes
showing changes over time. Furthermore, RT dosimetry could
not be evaluated due to the fact that at the time most of the
patients had received RT the data were not stored, precluding
accurate retrospective estimation of the radiation dose to the
heart. Finally, a selection bias cannot be ruled out. Twenty-
eight percent of the invited patients refused to participate,
which may have resulted in a selection bias as the prevalence
of cardiac failure in non-participants is unknown. It cannot be
ruled out that survivors who are sicker feel more encouraged
to participate compared to those who feel healthy. Non-par-
ticipants had a somewhat shorter duration of follow-up com-
pared to the participants, which may have resulted in
overestimation of the prevalence of cardiac damage, since
an association has been suggested between duration of fol-
low-up and cardiac damage.15,44
We concluded that childhood cancer survivors who have
been treated with potentially cardiovascular-toxic treatment
have an increased prevalence of both systolic and diastolic
dysfunction as compared to sibling controls. Moreover, a
higher anthracycline dose and chest RT were associated with
both systolic and diastolic dysfunction. Since these abnor-
malities, in particular diastolic dysfunction, are more com-
mon in the elderly, these observed effects might be
interpreted as a form of precocious cardiac ageing. Further re-
search is warranted to test this hypothesis. In addition stud-
ies are also needed to determine the most appropriate and
usable method for determination of systolic function in
CCS. To determine the clinical relevance of diastolic dysfunc-
tion in this particular population of cancer survivors, there is
a need for prospective longitudinal studies on systolic and
diastolic cardiac function in CCS. In addition, associated risk
factors, such as hypertension and overweight, require further
exploration as potential intervention targets.Role of the funding source
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